thiotepa

Summary

Summary: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).

Top Publications

  1. ncbi The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation
    Michael W Schuster
    Weill Medical College of Cornell University, New York, NY, USA
    Exp Hematol 30:1044-50. 2002
  2. ncbi Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue
    Halldora K Thorarinsdottir
    Division of Hematology and Oncology, Children s National Medical Center, Washington, District of Columbia, USA
    Pediatr Blood Cancer 48:278-84. 2007
  3. ncbi Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
    M Montemurro
    Department of Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Sauerbruchstrasse, 17475 Greifswald, Germany
    Ann Oncol 18:665-71. 2007
  4. ncbi Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer
    Okan Kuzhan
    GATA School of Medicine, Department of Medical Oncology, Etlik, Ankara, Turkey
    Tumori 93:550-6. 2007
  5. ncbi Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
    Ignazio Majolino
    Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Leuk Lymphoma 48:759-66. 2007
  6. ncbi Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications
    Y Xu
    Department of Pediatrics, Section of Hematology/Oncology, Herman B. Wells Center for Pediatric Research and Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    J Pharmacol Exp Ther 296:825-31. 2001
  7. ncbi Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia
    Neerav Shukla
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 61:431-5. 2014
  8. ncbi Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa
    J Barek
    Department of Analytical Chemistry, Charles University, Prague, Czech Republic
    Ann Occup Hyg 42:259-66. 1998
  9. ncbi Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, and Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Ther Drug Monit 27:756-65. 2005
  10. ncbi Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA
    P A Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, 308 Harvard Street S E, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Chemother Pharmacol 49:461-7. 2002

Detail Information

Publications232 found, 100 shown here

  1. ncbi The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation
    Michael W Schuster
    Weill Medical College of Cornell University, New York, NY, USA
    Exp Hematol 30:1044-50. 2002
    ..To assess the safety and efficacy of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) administered after autologous bone marrow transplantation (ABMT)...
  2. ncbi Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue
    Halldora K Thorarinsdottir
    Division of Hematology and Oncology, Children s National Medical Center, Washington, District of Columbia, USA
    Pediatr Blood Cancer 48:278-84. 2007
    ....
  3. ncbi Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkol
    M Montemurro
    Department of Internal Medicine C, Hematology and Oncology, Stem Cell Transplantation, Ernst Moritz Arndt University, Sauerbruchstrasse, 17475 Greifswald, Germany
    Ann Oncol 18:665-71. 2007
    ..the efficacy and safety of tandem high-dose methotrexate (HD-MTX) induction followed by high-dose busulfan/thiotepa (HD-BuTT) with autologous peripheral blood stem-cell transplantation (aPBSCT) and response-adapted whole-brain ..
  4. ncbi Survival benefit with GM-CSF use after high-dose chemotherapy in high-risk breast cancer
    Okan Kuzhan
    GATA School of Medicine, Department of Medical Oncology, Etlik, Ankara, Turkey
    Tumori 93:550-6. 2007
    ..We compared survival differences in patients receiving human granulocyte-colony stimulating factor (G-CSF) or granulocyte-monocyte colony stimulating factor (GM-CSF) after high-dose chemotherapy with stem cell support...
  5. ncbi Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma
    Ignazio Majolino
    Hematology and Bone Marrow Transplantation Unit, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
    Leuk Lymphoma 48:759-66. 2007
    ..The thiotepa, fludarabine, and melphalan conditioning regimen can produce remissions in the majority of MM patients with a ..
  6. ncbi Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications
    Y Xu
    Department of Pediatrics, Section of Hematology/Oncology, Herman B. Wells Center for Pediatric Research and Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    J Pharmacol Exp Ther 296:825-31. 2001
    ..N,N',N"-triethylenethiophosphoramide (thiotepa), a polyfunctional alkylating agent, is used in the treatment of breast, ovarian, and bladder carcinomas and is ..
  7. ncbi Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia
    Neerav Shukla
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York
    Pediatr Blood Cancer 61:431-5. 2014
    ..In an effort to improve outcomes, we performed a phase I/II study of a novel clofarabine based combination regimen called TVTC. Herein, we report the response rates of patients in the phase II portion of the study...
  8. ncbi Chemical degradation of wastes of antineoplastic agents amsacrine, azathioprine, asparaginase and thiotepa
    J Barek
    Department of Analytical Chemistry, Charles University, Prague, Czech Republic
    Ann Occup Hyg 42:259-66. 1998
    ..H2O2, 30%), were tested for the degradation of four anticancer drugs: Amsacrine, Azathioprine, Asparaginase and Thiotepa. The efficiency of the degradation was monitored by high-performance liquid chromatography...
  9. ncbi Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, and Faculty of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands
    Ther Drug Monit 27:756-65. 2005
    ..This activation pathway is inhibited by thiotepa. CP is inactivated by formation of 2-dechloroethylcyclophosphamide (2DCECP)...
  10. ncbi Cytochrome P450 isozymes 3A4 and 2B6 are involved in the in vitro human metabolism of thiotepa to TEPA
    P A Jacobson
    Experimental and Clinical Pharmacology, College of Pharmacy, 308 Harvard Street S E, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Chemother Pharmacol 49:461-7. 2002
    To establish the cytochrome P450 (CYP) isozymes involved in the metabolism of the alkylating agent, thiotepa, to the pharmacologically active metabolite, TEPA.
  11. pmc Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases
    Carole Soussain
    Department of Hematology, Hôpital René Huguenin, Institut Curie, Saint Cloud, France
    Haematologica 97:1751-6. 2012
    ....
  12. ncbi Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066, EC, Amsterdam, The Netherlands
    Cancer Chemother Pharmacol 56:370-8. 2005
    Patients receiving the highly emetogenic high-dose chemotherapy regimen with cyclophosphamide, thiotepa and carboplatin (CTC) may benefit from the neurokin-1 receptor antagonist aprepitant in addition to standard anti-emetic therapy...
  13. ncbi Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin
    Corine Ekhart
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, The Netherlands
    Pharmacogenet Genomics 18:1009-15. 2008
    High-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin (CTC) has been developed as a possible curative treatment modality in several solid tumours...
  14. ncbi A comparison of 2-phenyl-2-(1-piperidinyl)propane (ppp), 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine as selective inactivators of human cytochrome P450 2B6
    Robert L Walsky
    Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Pfizer, Inc, Groton, CT 06340, USA
    Drug Metab Dispos 35:2053-9. 2007
    ..CYP2B6 and compare this selectivity versus other CYP2B6 inactivators: 1,1',1''-phosphinothioylidynetrisaziridine (thioTEPA), clopidogrel, and ticlopidine. Values of K(I) and k(inact) for PPP were 5.6 microM and 0...
  15. ncbi Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens
    A D Huitema
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam
    Cancer Chemother Pharmacol 46:119-27. 2000
    Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens...
  16. ncbi A comprehensive understanding of thioTEPA metabolism in the mouse using UPLC-ESI-QTOFMS-based metabolomics
    Fei Li
    Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20852, USA
    Biochem Pharmacol 81:1043-53. 2011
    b>ThioTEPA, an alkylating agent with anti-tumor activity, has been used as an effective anticancer drug since the 1950s...
  17. pmc Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma
    Maura Massimino
    Pediatric Oncology Unit, Istituto Nazionale Tumori, Milan, Italy
    Neuro Oncol 7:41-8. 2005
    ..Our study protocol incorporated sequential chemotherapy and high-dose thiotepa in the preradiant phase, followed by focal radiotherapy and maintenance with vincristine and lomustine for a ..
  18. ncbi Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study
    Andrew L Gilman
    Levine Children s Hospital, Charlotte, NC, USA
    Pediatr Blood Cancer 57:506-13. 2011
    ..A Phase I trial of two cycles of HDC/SCR for recurrent brain tumors in children was performed to determine the maximum tolerated doses for a novel regimen...
  19. pmc The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors in mice
    Christopher M Mondie
    Department of Biology, Rider University, Lawrenceville, NJ 08648, USA
    Behav Brain Res 209:66-72. 2010
    b>ThioTEPA is a chemotherapeutic agent used in the treatment of cancers, and more recently has been proposed as a component of high-dose therapy for young patients with recurrent malignant brain tumors...
  20. ncbi Thiotepa/topotecan/carboplatin with autologous stem cell rescue in recurrent/refractory/poor prognosis pediatric malignancies of the central nervous system
    Stephen W Gilheeney
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Pediatr Blood Cancer 54:591-5. 2010
    b>Thiotepa and carboplatin are known to be active in central nervous system tumors. Topotecan potentiates the anti-cancer effects of alkylators and crosses the blood-brain barrier...
  21. doi The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma
    P Hiwarkar
    Leukemia 22:1627-9. 2008
  22. ncbi High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma
    T Cheng
    Department of Medicine, Tom Baker Cancer Centre, University of Calgary, Alta, Canada
    Bone Marrow Transplant 31:679-85. 2003
    ..upon these dismal results, we treated seven PCNSL patients with HD-MTX-based induction therapy followed by thiotepa, busulfan, cyclophosphamide (TBC), and autologous stem cell transplant (ASCT), without WBRT...
  23. ncbi Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study
    J Bergh
    Radiumhemmet, Karolinska Hospital, Stockholm, Sweden
    Lancet 356:1384-91. 2000
    ..We then did a randomised trial to compare this individually tailored FEC regimen with conventional adjuvant chemotherapy followed by consolidation with high-dose chemotherapy with stem-cell support...
  24. ncbi Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer
    J G Schrama
    Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Bone Marrow Transplant 28:173-80. 2001
    ..was to determine the feasibility and efficacy of multiple courses of high-dose cyclophosphamide, carboplatin and thiotepa with peripheral blood progenitor cell (PBPC) transplantation in women with advanced breast cancer...
  25. pmc Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy
    A D Huitema
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Br J Clin Pharmacol 51:61-70. 2001
    To study the population pharmacokinetics of thioTEPA and its main metabolite TEPA in patients receiving high-dose chemotherapy consisting of thioTEPA (80-120 mg x m(-2) x day(-1)), cyclophosphamide (1000-1500 mg x m(-2) x day(-1)) and ..
  26. ncbi Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: an active and well-tolerated regimen
    M Colleoni
    Division of Medical Oncology and Service of Cardiology, European Institute of Oncology, Milan, Italy
    J Clin Oncol 16:2371-6. 1998
    ..We analyzed the results of our current treatment policy to evaluate the effectiveness and tolerance of a new approach for this disorder...
  27. ncbi Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa
    Alessandro Martinoni
    Cardiology Unit, Via Ripamonti 435, Milan, Italy
    Chest 126:1412-6. 2004
    ..This study was performed in order to investigate the long-term effects of intracavitary treatment with thiotepa in the reduction of pericardial effusion (PE) recurrences.
  28. ncbi High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer
    Sjoerd Rodenhuis
    Netherlands Cancer Institute, Department of Medical Oncology, Amsterdam, The Netherlands
    N Engl J Med 349:7-16. 2003
    ..The use of high-dose adjuvant chemotherapy for high-risk primary breast cancer is controversial. We studied its efficacy in patients with 4 to 9 or 10 or more tumor-positive axillary lymph nodes...
  29. ncbi Retrovirus-mediated expression of the base excision repair proteins, formamidopyrimidine DNA glycosylase or human oxoguanine DNA glycosylase, protects hematopoietic cells from N,N',N"-triethylenethiophosphoramide (thioTEPA)-induced toxicity in vitro
    M Kobune
    Section of Pediatric Hematology/Oncology, Herman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Cancer Res 61:5116-25. 2001
    ..N,N',N"-Triethylenethiophosphoramide (thioTEPA) induces the formation of amino-ethyl adducts of guanine, resulting in imidazole ring opening [..
  30. ncbi High-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group
    I J Dunkel
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 16:222-8. 1998
    ..Very few patients survive with conventional treatment. This study evaluated the use of high-dose carboplatin, thiotepa, and etoposide with autologous stem-cell rescue (ASCR) in patients with recurrent medulloblastoma.
  31. ncbi Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA
    Robert G Mignone
    Department of Biochemistry, Rider University, Lawrenceville, NJ 08648 USA
    Brain Res 1111:26-9. 2006
    ..We have examined whether several such drugs capable of penetrating the blood-brain barrier - thioTEPA and 5-fluorouracil - influence the normal process of cell proliferation underlying neurogenesis in the dentate ..
  32. ncbi Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    Athanasios Anagnostopoulos
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2607-12. 2004
    ..In the current study, the authors compared the outcomes associated with high-dose melphalan (HDM) and a more intensive regimen of thiotepa, busulfan, and cyclophosphamide (TBC) in patients with multiple myeloma.
  33. ncbi Thiotepa-based high-dose chemotherapy with autologous stem-cell rescue in patients with recurrent or progressive CNS germ cell tumors
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 22:1934-43. 2004
    ..To evaluate the efficacy and toxicity of high-dose chemotherapy (HDC) followed by autologous stem-cell rescue (ASCR) in patients with relapsed or progressive CNS germ cell tumors (GCTs)...
  34. ncbi Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer
    P Biron
    Centre Leon Berard, Lyon, France
    Bone Marrow Transplant 41:555-62. 2008
    ..Patients with objective response (N=179) were randomized to one cycle of HDC (cyclophosphamide 6000 mg/m(2) and thiotepa 800 mg/m(2) (CHUT)) and stem cell support (N=88), or no further treatment (N=91)...
  35. ncbi Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin
    Yvonne Brandberg
    Department of Oncology, Karolinska Hospital, S 171 76 Stockholm, Sweden
    J Clin Oncol 21:3659-64. 2003
    ..and cyclophosphamide (FEC) therapy for nine courses versus induction FEC therapy for three courses followed by high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin (CTCb) supported by peripheral-blood stem cells.
  36. ncbi High-dose thiotepa and etoposide in children with poor-prognosis brain tumors
    Franca Fagioli
    Department of Pediatrics, Regina Margherita Children s Hospital, University of Turin, Turin, Italy
    Cancer 100:2215-21. 2004
    ..or newly diagnosed high-risk brain tumors and who underwent high-dose chemotherapy with triethylenethiophosphoramide (thiotepa) and etoposide in addition to autologous stem cell transplantation between May 1992 and September 2002.
  37. ncbi A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia
    E A Kolb
    Department of Pediatrics at Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Leukemia 17:1967-72. 2003
    ..28 patients with multiple relapsed or refractory acute leukemia received a combination of topotecan, vinorelbine, thiotepa, dexamethasone, and, for patients with an M3 marrow on day 7, gemcitabine...
  38. ncbi Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age
    A M Raiola
    Dipartimento di Ematologia DEMA, Ospedale San Martino, Dipartimento Medicina Interna DIMI and Cattedra Medicina Legale, Univesita, Genova, Italy
    Br J Haematol 109:716-21. 2000
    ..The regimen consisted of thiotepa (THIO; 10 mg/kg) on day -5 and cyclophosphamide (CY; 50 mg/kg) on days -3 and -2 (total dose 100 mg/kg)...
  39. pmc Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa
    Corine Ekhart
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Br J Clin Pharmacol 67:50-60. 2009
    b>Thiotepa is widely used in high-dose chemotherapy. Previous studies have shown relations between exposure and severe organ toxicity. Thiotepa is metabolized by cytochrome P450 and glutathione S-transferase enzymes...
  40. ncbi Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    J Pharmacokinet Pharmacodyn 31:135-56. 2004
    Cyclophosphamide (CP) and thiotepa (TT) are frequently administered simultaneously in high-dose chemotherapy regimens...
  41. ncbi Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
    S Rodenhuis
    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam
    Lancet 352:515-21. 1998
    ..Many physicians accept this treatment as standard care. We aimed to assess adjuvant high-dose chemotherapy in breast cancer in a phase II randomised trial...
  42. ncbi Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group
    E A Stadtmauer
    Bone Marrow and Stem Cell Transplant Program, University of Pennsylvania Cancer Center, Philadelphia 19104, USA
    N Engl J Med 342:1069-76. 2000
    ..We conducted a randomized trial in which we compared high-dose chemotherapy plus hematopoietic stem-cell rescue with a prolonged course of monthly conventional-dose chemotherapy in women with metastatic breast cancer...
  43. ncbi Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors
    D Hawkins
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Med Pediatr Oncol 34:328-37. 2000
    ..We describe the toxicity and efficacy of a myeloablative chemotherapy regimen, followed by a second myeloablative radiotherapy regimen as consolidation treatment for poor-risk ESFT...
  44. ncbi Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin
    A D R Huitema
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam
    Ann Oncol 13:374-84. 2002
    ..The aim of this study was to establish the pharmacokinetics of cyclophosphamide, thiotepa, carboplatin and all relevant metabolites in a widely used high-dose combination and to study possible ..
  45. ncbi Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer
    O Rick
    Department of Hematology, , Campus Virchow Klinikum, Berlin, Germany
    J Clin Oncol 19:81-8. 2001
    ..by one cycle of high-dose chemotherapy (HDCT) with carboplatin 500 mg/m(2) x 3, etoposide 600 mg/m(2) x 4, and thiotepa 150 to 250 mg/m(2) x 3 (CET)...
  46. ncbi A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors
    Amy Rosenfeld
    Center for Cancer and Blood Disorders, Phoenix Children s Hospital, 1919 East Thomas Road, Phoenix, AZ, 85016, USA
    J Neurooncol 97:247-55. 2010
    ..Cytoreduction regimen #1 consisted of carboplatin (500 mg/m(2)) x 3 days, etoposide (250 mg/m(2)) x 3 days, and thiotepa (300 mg/m(2)) x 3 days...
  47. ncbi Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients
    C L Shapiro
    Breast Evaluation Center, Department of Biostatistics, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 15:674-83. 1997
    As an alternative to single-cycle cyclophosphamide, thiotepa, and carboplatin (CTCb) intensification, we evaluated the feasibility of administering one-quarter dose CTCb for four cycles with peripheral-blood progenitor-cell (PBPC) and ..
  48. ncbi A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide
    A D Huitema
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    J Pharmacokinet Pharmacodyn 28:211-30. 2001
    Cyclophosphamide (CP) is widely used in high-dose chemotherapy regimens in combination with thioTEPA. CP is a prodrug and is activated by cytochrome P450 to 4-hydroxycyclophosphamide (HCP) which yields the final cytotoxic metabolite ..
  49. ncbi Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen
    A D Huitema
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam, The Netherlands
    Ther Drug Monit 23:650-7. 2001
    b>Thiotepa is an alkylating agent widely used in high-dose chemotherapy...
  50. ncbi Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer
    Martin S Tallman
    Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago 60611, USA
    N Engl J Med 349:17-26. 2003
    ..High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse...
  51. pmc High-dose carboplatin, thiotepa and cyclophosphamide (CTC) with peripheral blood stem cell support in the adjuvant therapy of high-risk breast cancer: a practical approach
    E van der Wall
    Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam
    Br J Cancer 71:857-62. 1995
    ..in 26 patients; 28 patients subsequently underwent high-dose chemotherapy consisting of carboplatin 1600 mg m-2, thiotepa 480 mg m-2 and cyclophosphamide 6 g m-2 (CTC) followed by PBSC transplantation...
  52. ncbi Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography
    A D Huitema
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Amsterdam
    J Chromatogr B Biomed Sci Appl 716:177-86. 1998
    A sensitive assay for the simultaneous determination of N,N',N"-triethylenethiophosphoramide (thioTEPA), its metabolite N,N',N"-triethylenephosphoramide (TEPA), cyclophosphamide (CP) and its metabolite 2-dechloroethylcyclophosphamide (2-..
  53. ncbi High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC)
    C Bengala
    Department of Oncology Transplants ancd Advanced Technologies in Medicine, St. Chiara Hospital and University of Pisa, Italy
    Ann Oncol 12:69-74. 2001
    ..After six courses of epirubicin-paclitaxel +/- gemcitabine patients received a course of thiotepa 600 mg/m2 + melphalan 160 mg/m2 with hemopoietic support...
  54. pmc Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
    L J van Warmerdam
    Department of Medical Oncology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Br J Cancer 73:979-84. 1996
    ..in patients treated with high dose carboplatin (400 mg m-2 day-1), cyclophosphamide (1500 mg m-2 day-1) and thiotepa (120 mg m-2 day-1) for four consecutive days, followed by peripheral stem cell transplantation...
  55. ncbi Phase I/pharmacokinetic reevaluation of thioTEPA
    P J O'Dwyer
    Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111
    Cancer Res 51:3171-6. 1991
    Because the initial evaluation of N,N',N''-triethylenethiophosphoramide (thioTEPA) preceded the standardized approach to the Phase I trials, uncertainty surrounds the recommended dose...
  56. ncbi Liquid chromatography-thermospray mass spectrometry of DNA adducts formed with mitomycin C, porfiromycin and thiotepa
    S M Musser
    Department of Medicinal Chemistry and Pharmacognosy, School of Pharmacy, University of Maryland, Baltimore 21201
    J Chromatogr 474:197-207. 1989
    ..for the analysis of DNA adducts formed from the interaction of the anticancer drugs mitomycin C, porfiromycin and thiotepa with calf thymus DNA...
  57. ncbi Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma
    James Rook
    Department of Pediatrics, Loma Linda University Children s Hospital, Loma Linda University School of Medicine, Loma Linda, California, USA
    Pediatr Blood Cancer 50:699-700. 2008
    ..We present the case of a 14-year-old female with a recurrent suprasellar germinoma who developed an acute encephalopathy 4-6 hr following paclitaxel infusion...
  58. ncbi T1-T2 breast cancer with four or more positive axillary lymph nodes: adjuvant locoregional radiotherapy with high-dose or standard-dose chemotherapy. Results of an observational study
    Elisabetta Perrucci
    Radiotherapy Oncology, Policlinico Hospital and University of Perugia, Italy
    Tumori 90:379-86. 2004
    ..The incidence of locoregional relapses and the survival correlated with the number of positive nodes were recorded for each treatment arm...
  59. ncbi High-dose chemotherapy with autologous stem cell rescue in children with nephroblastoma
    B Kremens
    Department of Pediatric Hematology Oncology, University of Essen, Germany
    Bone Marrow Transplant 30:893-8. 2002
    ..Besides hematological toxicity, mucositis and infections, renal function is at risk during HDC. With dose adjustment on glomerular filtration rate, however, no permanent renal failure was observed...
  60. ncbi Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study
    M D Stubblefield
    Department of Neurology, Rehabilitation Service, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York City, NY 10021, USA
    Clin Oncol (R Coll Radiol) 17:271-6. 2005
    ..The appearance of peripheral neuropathy is the dose-limiting toxicity in many chemotherapy protocols, and glutamine has been proposed as a potentially neuroprotective agent in patients receiving paclitaxel...
  61. ncbi Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients
    S M Stemmer
    Department of Oncology and Radiotherapy, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Bone Marrow Transplant 31:655-61. 2003
    ..For this high-risk patient population, further testing of intensive chemotherapy regimens with a lower toxicity profile is warranted...
  62. pmc Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience
    J G Schrama
    Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 88:1831-8. 2003
    ..6000 mg m(-2), carboplatin 1600 mg m(-2) (or 20 mg ml(-1) min under the curve (AUC)) both as daily 1 h infusion, thiotepa 480 mg m(-2) as twice daily 30 min infusion, all divided over 4 consecutive days) followed by peripheral blood ..
  63. ncbi Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy
    Milly E de Jonge
    Department of Pharmacy and Pharmacology, Slotervaart Hospital, Amsterdam, The Netherlands
    Clin Cancer Res 11:273-83. 2005
    Relationships between toxicity and pharmacokinetics have been shown for cyclophosphamide, thiotepa, and carboplatin (CTC) in high-dose chemotherapy...
  64. ncbi Breast cancer-specific mRNA transcripts presence in peripheral blood after adjuvant chemotherapy predicts poor survival among high-risk breast cancer patients treated with high-dose chemotherapy with peripheral blood stem cell support
    Miguel Quintela-Fandino
    Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
    J Clin Oncol 24:3611-8. 2006
    ....
  65. ncbi Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer
    R Wong
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 31:1157-63. 2003
    ..for idiopathic pneumonia syndrome (IPS) after high-dose chemotherapy with cyclophosphamide, carmustine, and thiotepa followed by autologous stem cell transplantation for high-risk breast cancer...
  66. ncbi High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation
    T Demirer
    Ankara Numune Education and Research Hospital, Turkey
    Bone Marrow Transplant 31:755-61. 2003
    This study was conducted to evaluate the efficacy of high-dose thiotepa, melphalan and carboplatin (TMCb) regimen in 27 patients undergoing autologous stem cell transplantation (ASCT) for metastatic breast cancer...
  67. ncbi Palliative chemotherapy after failure of high-dose chemotherapy in breast cancer--toxicity and efficacy
    J G Schrama
    Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Anticancer Res 23:2795-800. 2003
    ..or metastatic breast cancer treated with high-dose chemotherapy (one full dose CTC, (cyclophosphamide 6000 mg/m2, thiotepa 480 mg/m2, carboplatin 1600 mg/m2) or multiple courses CTC or 'tiny' CTC (tCTC) (two-thirds of the agents of the ..
  68. ncbi Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue
    Stergios Zacharoulis
    Department of Pediatric Hematology Oncology, Children s Hospital Los Angdes, Neural Tumors Program, Los Angles, CA 900 27, USA
    Pediatr Blood Cancer 49:34-40. 2007
    ....
  69. ncbi High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer
    Salomon M Stemmer
    Bone Marrow Transplant Service, Department of Oncology and Radiotherapy, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 27:250-5. 2004
    ..The use of HDCT in patients with chemosensitive, de novo metastatic breast cancer is safe and well tolerated. Overall clinical outcome is good; however, this study cannot determine whether this was due to treatment or selection bias...
  70. ncbi High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: superior survival for tandem compared with single transplants
    Robert O Dillman
    Hoag Cancer Center, Newport Beach, California 92658, USA
    Am J Clin Oncol 28:281-8. 2005
    ..HDC regimens were MiTepa (60 mg/m2 mitoxantrone by continuous intravenous infusion over 3 days plus 300 mg/m2 thiotepa intravenously over 2 hours daily x 3 days) and ICE (12 g/m2 ifosfamide, 1800 mg/m2 carboplatin, 2 g/m2 etoposide; ..
  71. ncbi A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement
    H Matsubara
    Pediatric Oncology Division, National Cancer Center Hospital, Tokyo, Japan
    Bone Marrow Transplant 35:763-6. 2005
    ..and was administered in combination with other agents such as cisplatin, cyclophosphamide, carboplatin or thiotepa. Three patients are currently alive disease-free at 113, 107 and 38 months, respectively, from the time of SCT...
  72. ncbi Oral fluconazole for empiric treatment of prolonged Fever in neutropenic patients: prospective study in 250 consecutive patients after stem cell transplantation
    Salomon M Stemmer
    Bone Marrow Transplant Service, Department of Oncology and Radiotherapy, Chaim Sheba Medical Center, Tel Hashomer, Israel
    Am J Clin Oncol 27:328-32. 2004
    ..Further study of oral fluconazole and amphotericin B as empirical agents in other groups of patients with persistent neutropenic fever is warranted...
  73. ncbi High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer
    Uzair B Chaudhary
    UCSF Comprehensive Cancer Center, University of California, San Francisco, California, USA
    Am J Clin Oncol 28:130-7. 2005
    A phase I/II trial with high-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue (AHSCT) as treatment for patients with relapsed or refractory germ cell cancer was investigated...
  74. ncbi [Refractory germ cell cancer of testis treated by salvage high-dose chemotherapy: report of three cases]
    Susumu Tanji
    Department of Urology, Iwate Medical University School of Medicine
    Hinyokika Kiyo 50:77-80. 2004
    ..received one course of high-dose CEI and high-dose CCT (carboplatin 800 mg/m2, cyclophosphamide 6 g/m2 and thiotepa 720 mg/m2)...
  75. ncbi Thiotepa/cyclophosphamide/TBI as a conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome
    K Fujimaki
    First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama, Japan
    Bone Marrow Transplant 33:789-92. 2004
    ..underwent allogeneic HSCT from related (n=12) or unrelated (n=6) donors after a conditioning regimen comprising thiotepa, cyclophosphamide, and TBI...
  76. ncbi Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy
    Maura Massimino
    Neuro Oncology Functional Unit, Department of Pediatric Oncology, Istituto Nazionale Tumori, Milan, Italy
    Int J Radiat Oncol Biol Phys 64:1031-7. 2006
    ..Supratentorial primitive neuroectodermal tumors (S-PNET) are rare and have a grim prognosis, frequently taking an aggressive course with local relapse and metastatic spread. We report the results of a mono-institutional therapeutic trial...
  77. ncbi High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy
    Brian H Kushner
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Pediatr Blood Cancer 48:430-4. 2007
    ..We assessed the impact on rapid HAMA formation of prior chemotherapy in NB patients...
  78. ncbi Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients
    N Kroger
    Department of Bone Marrow Transplantation, University of Hamburg, Hamburg, Germany
    Bone Marrow Transplant 32:1153-7. 2003
    ..She achieved CR after induction therapy, but relapsed and expired 28 months after diagnosis of AML. sAML after mitoxantrone-based HDCT is a possible, but rare complication in breast cancer patients...
  79. ncbi Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer
    Amy Tiersten
    Department of Medical Oncology, NYU Medical Center, 160 East 32nd Street, Second Floor, New York, NY 10016, USA
    Breast 13:341-6. 2004
    ..Cyclophosphamide is an alkylating agent given frequently as a component of many conditioning regimens. In high doses, its nonhematological dose-limiting toxicity is cardiomyopathy...
  80. pmc High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
    M E de Jonge
    Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, The Netherlands
    Br J Cancer 94:1226-30. 2006
    ..Patients received single or multiple courses of cyclophosphamide (1000 or 1500 mg m-2 day-1), thiotepa (80 or 120 mg m-2 day-1) and carboplatin (265-400 mg m-2 day-1) (CTC) for 4 consecutive days...
  81. ncbi High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma -- a retrospective evaluation
    T Demirer
    Department of Hematology Oncology, Ankara University Medical School, Ankara, Turkey
    Bone Marrow Transplant 34:781-6. 2004
    The purpose of this evaluation was to investigate the efficacy of high-dose chemotherapy with thiotepa, melphalan, and carboplatin (TMCb), and of autologous peripheral blood stem cell (PBSC) infusion in patients with aggressive non-..
  82. ncbi The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy
    Yee Chung Cheng
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:794-804. 2004
    We assessed the 5-year results of a high-dose cyclophosphamide, carmustine, and thiotepa (CBT) regimen plus autologous hematopoietic stem cell transplantation (AHST) as an adjuvant consolidation therapy for high-risk primary breast cancer ..
  83. ncbi Randomized Phase II trial of two high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study
    Patrick J Stiff
    Loyola University Stritch School of Medicine, Maywood, IL 60153, USA
    Gynecol Oncol 94:98-106. 2004
    ....
  84. ncbi Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey
    Corrado Tarella
    Dipartimento Medicina Oncologia Sperimentale, Divisione Universitaria di Ematologia, Az Osp S Giovanni Battista, Via Genova 3, 10126 Torino, Italy
    J Clin Oncol 26:3166-75. 2008
    ..To investigate the impact of adding rituximab to intensive chemotherapy with peripheral-blood progenitor cell (PBPC) autograft for high-risk diffuse large B-cell lymphoma (DLB-CL) and follicular lymphoma (FL)...
  85. ncbi Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy
    F Morabito
    Centro Trapianti di Midollo Osseo, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
    Bone Marrow Transplant 28:883-8. 2001
    ..In conclusion, MBC patients treated with a conditioning regimen containing only one alkylating agent and adequate prophylaxis for mucositis may qualify for outpatient-based PBSCT on the basis of a lower risk of infection...
  86. ncbi Randomized trial of low-dose interleukin-2 vs cyclosporine A and interferon-gamma after high-dose chemotherapy with peripheral blood progenitor support in women with high-risk primary breast cancer
    L T Vahdat
    Weill Medical College of Cornell University, New York, NY 10021, USA
    Bone Marrow Transplant 40:267-72. 2007
    ..78)) and a 72% OS (95% CI (0.58, 0.88)) at 5 years. The CsA/INF-gamma arm had a similar outcome with a 55% DFS (95% CI (0.40, 0.76)) and a 78% OS (95% CI (0.65, 0.94)) at 5 years. Treatment was well tolerated, without increased toxicity...
  87. ncbi Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function
    S B Schagen
    Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam
    J Neurooncol 51:159-65. 2001
    ....
  88. pmc Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation
    C P Schröder
    Department of Medical Oncology, University Hospital Groningen, The Netherlands
    Br J Cancer 84:1348-53. 2001
    ..courses FEC (5-FU, epirubicin and cyclophosphamide) (n = 17), or 4 x FEC followed by high-dose cyclophosphamide, thiotepa, carboplatin and autologous PBSCT (n = 16)...
  89. ncbi Recurrent disseminated retinoblastoma in a 7-year-old girl treated successfully by high-dose chemotherapy and CD34-selected autologous peripheral blood stem cell transplantation
    H Hertzberg
    University Hospital for Children and Adolescents, , Germany
    Bone Marrow Transplant 27:653-5. 2001
    ..Subsequent high-dose chemotherapy with thiotepa, etoposide and carboplatin and autologous stem cell transplantation with CD34-selected stem cells were successful,..
  90. ncbi Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life
    Ciska Buijs
    University Medical Center Groningen and University of Groningen, Groningen, The Netherlands
    J Clin Oncol 25:5403-9. 2007
    ..To evaluate and compare health-related quality of life (HRQOL) after conventional- and high-dose adjuvant chemotherapy in patients with high-risk breast cancer...
  91. ncbi Treatment of children with metastatic soft tissue sarcoma with oral maintenance compared to high dose chemotherapy: report of the HD CWS-96 trial
    Thomas Klingebiel
    Children s Hospital of Frankfurt University Hospital, Frankfurt, Germany
    Pediatr Blood Cancer 50:739-45. 2008
    ..We prospectively studied the efficacy of high dose therapy (HDT) versus an oral maintenance treatment (OMT) in patients with stage IV soft tissue sarcoma (STS)...
  92. ncbi Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up
    A R Zander
    Center of Oncology, Clinic for Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Ann Oncol 19:1082-9. 2008
    ..v. (every 21 days) and either HD-CT of cyclophosphamide (1500 mg/m(2)), thiotepa (150 mg/m(2)) and mitoxantrone (10 mg/m(2)) i.v...
  93. ncbi Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
    Carole Soussain
    Department of Hematology, Biostatistics Unit, Centre Rene Huguenin, Saint Cloud, France
    J Clin Oncol 26:2512-8. 2008
    ....
  94. ncbi Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital
    Andrew D Campbell
    Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL 60614, USA
    J Clin Oncol 22:2885-90. 2004
    ..To investigate whether high-dose therapy with hematopoietic stem-cell rescue (HSCR) will improve survival for patients with relapsed Wilms' tumor...
  95. ncbi The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients
    Ugo De Giorgi
    Department of Oncology and Hematology, Santa Maria delle Croci Hospital, Viale Randi 5, 48100 Ravenna, Italy
    Haematologica 87:95-104. 2002
    ..This paper presents an update of available information in order to define the status of HDCT in GCT patients...
  96. ncbi Brainstem primitive neuroectodermal tumors (bstPNET): results of treatment with intensive induction chemotherapy followed by consolidative chemotherapy with autologous hematopoietic cell rescue
    Jason R Fangusaro
    The Children s Hospital Los Angeles, New York University Medical Center, Memorial Sloan Kettering Cancer Center, and Schneider Children s Hospital, USA
    Pediatr Blood Cancer 50:715-7. 2008
    ..Two patients survive at least 32 months with stable disease. This approach provides an alternative for young patients with bstPNET who in prior reports have had a uniformly fatal prognosis...
  97. ncbi Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer
    L T Vahdat
    Weill Cornell Medical College, New York, NY 10021, USA
    Bone Marrow Transplant 30:149-55. 2002
    ..second melphalan (180 mg/m(2)) and the third consisted of cyclophosphamide 6000 mg/m(2) (1500 mg/m(2)/day x 4), thiotepa 500 mg/m(2) (125 mg/m(2)/day x 4) and carboplatin 800 mg/m(2) (200 mg/m(2)/day x 4) (CTCb)...
  98. ncbi Isolex 300i CD34-selected cells to support multiple cycles of high-dose therapy
    H M Prince
    Blood and Marrow Transplant Service, Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Australia
    Cytotherapy 4:137-45. 2002
    ..Here we investigate whether purified CD34+ cells, obtained by immunomagnetic separation using the Isolex 300i device, can support such therapy...
  99. ncbi Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance
    Charlotte Kloft
    Department of Clinical Pharmacy, Freie Universitaet Berlin, Germany
    J Clin Pharmacol 42:762-73. 2002
    ..Since the fraction unbound is time dependent and highly variable among patients, measuring ultrafiltered concentrations is highly recommended as they represent the clinically relevant platinum complexes in high-dose treatment...
  100. ncbi The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farbe
    A D Elias
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Biol Blood Marrow Transplant 8:198-205. 2002
    ..or complete response to an unspecified induction therapy and treated them with high-dose CTCb (cyclophosphamide, thiotepa, and carboplatin) supported by marrow or peripheral blood progenitor cells (PBPC)...
  101. pmc Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy
    J Hannemann
    Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Br J Cancer 95:1334-41. 2006
    ..Possibly, the difference of the cumulative dose of only 25% between the treatment arms was insufficient to yield a survival difference...

Research Grants28

  1. EFFECTS OF CHEMOTHERAPY AGENTS ON NEUROGENESIS IN ADULT MOUSE HIPPOCAMPUS
    EDWARD TODD WEBER; Fiscal Year: 2010
    ..will investigate cognitive and behavioral deficits resulting from administration of the chemotherapeutic drug thioTEPA in mice, in an effort to understand neurological and cognitive deficiencies experienced by humans subjected to ..
  2. Novel Targets in Cancer Chemotherapy: Chemical Biology of Guanine Alkylation
    Michael P Stone; Fiscal Year: 2013
    ..For alkylating agents such as temozolomide, thioTEPA, and nitrogen mustards, the most abundant lesion is formed at N7-guanine, with less abundant, but biologically ..
  3. DETECTION & REVERSAL OF OVARIAN CANCER DRUG RESISTANCE
    Robert Ozols; Fiscal Year: 1992
    ..cytotoxicity of melphalan and carboplatin, (2) ethacrynic acid to inhibit GST and potentiate the cytotoxicity of thioTEPA, and (3) aphidicolin to inhibit DNA polymerase alpha and thereby decrease DNA repair capacity and increase the ..
  4. ROLE OF HUMAN GST PI POLYMORPHISM IN DRUG RESISTANCE
    Shivendra Singh; Fiscal Year: 2003
    ..than the other variants of hGSTP1-1 in catalyzing the GSH conjugation (detoxification) of chlorambucil (CMB) and thiotepa (TT)...
  5. PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY
    JESSIE AU; Fiscal Year: 2003
    ..We propose to establish, for doxorubicin and thiotepa, (a) drug concentration-time profiles in blood and urine, (b) extent and rate of systemic absorption of drugs ..
  6. MODULATION OF HIGH-DOSE ALKYLATOR EFFICACY BY NOVOBIOCIN
    Michael Kennedy; Fiscal Year: 1992
    ..in-vitro efficacy, and mechanism of action of novobiocin in combination with high-dose cyclophosphamide and thiotepa for the treatment of metastatic breast cancer...
  7. Novel Therapies for High-Risk Neuroblastoma
    Julie Park; Fiscal Year: 2006
    ..BC8 (anti-CD45) antibody combined with the myeloablative chemotherapy regimen of topotecan, carboplatin and thiotepa in a Phase I trial treating patients with high risk neuroblastoma, with the goal of improving outcome by ..
  8. PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER
    JESSIE AU; Fiscal Year: 1991
    ..examine the pharmacokinetics and pharmacodynamics (drug concentration-time-effect relationship) of mitomycin C, thiotepa and doxorubicin which are used in the intravesical treatment of urinary bladder cancers...
  9. ANTINEOPLASTIC THERAPY TOXICITY IN THE DEVELOPING CNS
    Russ Geyer; Fiscal Year: 1993
    ..SEP and subsequent dose-dependent white matter change, including WMN; 3) Single bolus administration of MTX or thioTEPA results in dose-dependent alteration of SEP cell density...
  10. Measuring Cytogenetic Damage in Human Blood
    Stephen Dertinger; Fiscal Year: 2003
    ..abstract_text> ..
  11. CHILDRENS CANCER GROUP
    Peter Steinherz; Fiscal Year: 2002
    ..Members of the affiliate hospitals have been participating in CCG studies and have proven their ability to conduct the clinical studies and provide material for laboratory evaluation. ..
  12. Halogenated Alkenes and Microsomal GSH-transferases
    Michael J Kelner; Fiscal Year: 2010
    ..4] To determine the relative contribution of MGST1 and MGST2 to cellular antioxidant capacity through studies utilizing human MGST1 and MGST2 null cells. ..
  13. Rapid Screen for Genotoxicants, Chemoprotectors, and Radioprotectors
    Stephen Dertinger; Fiscal Year: 2008
    ..In addition, this assay can be used to investigate agents designed to ameliorate the effects of radiation exposure, e.g. biological response modifiers. [unreadable] [unreadable] [unreadable] [unreadable]..
  14. Participating Member Institution in NABTC
    Lisa DeAngelis; Fiscal Year: 2008
    ..abstract_text> ..
  15. CANCER GENETICS NETWORK
    Claudine Isaacs; Fiscal Year: 2006
    ....
  16. In vivo mutation assay based on pig-a locus
    Stephen Dertinger; Fiscal Year: 2004
    ....
  17. TARGETED RADIOTHERAPY FOR EWING'S SARCOMA
    Douglas Hawkins; Fiscal Year: 2005
    ....
  18. Versatile Mutation Assay Platform
    Stephen Dertinger; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. Automation of the vitro Micronucleus Assay
    Stephen Dertinger; Fiscal Year: 2004
    ..abstract_text> ..
  20. High Throughput Radiation Biodosimetry
    Stephen Dertinger; Fiscal Year: 2007
    ..We propose to develop such a radiation biodosimetry assay based on the extremely high analysis rates that are possible with flow cytometry instrumentation. [unreadable] [unreadable] [unreadable]..
  21. CARDINAL BERNARDIN CANCER CENTER, LOYOLA UNIVERSITY
    Patrick Stiff; Fiscal Year: 2002
    ..At the completion of this grant, the Cardinal Bernardin Cancer Center plans to be positioned to successfully apply for a P-30 Cancer Center Support Grant. ..
  22. Optimizing T cell Immunity to Cancer Vaccines
    Miguel Angel Perales; Fiscal Year: 2006
    ..This environment maximizes the potential for the principal investigator to establish a successful independent research program. [unreadable] [unreadable]..
  23. Occupational Pesticide Exposure of Parents and Brain Tumor Risk in Children
    Greta Bunin; Fiscal Year: 2008
    ..The proposed study will provide information on the usefulness of these approaches. [unreadable] [unreadable] [unreadable]..
  24. GPX1 ENZYME REGULATION BY OXIDATIVE XENOBIOTICS
    Michael Kelner; Fiscal Year: 2002
    ..These studies will provide critical information regarding cellular response to oxidative stress and aid in determining if a common regulatory mechanism exists for GSH-dependent enzymes. ..
  25. CONTROL SELECTION METHODS FOR CHILDHOOD CANCER STUDIES
    Greta Bunin; Fiscal Year: 2009
    ..A feasible and valid control group is needed to ensure that studies of childhood cancer are scientifically valid and therefore, will provide results that can eventually lead to prevention of these cancers. ..
  26. Optimizing Stem Cell Transplant for Cancer
    Pamala Jacobson; Fiscal Year: 2006
    ..host disease, graft failure, toxicity and improve survival following nonmyeloablative HSCT. The overall goal is to provide the applicant with formal and comprehensive training as a clinical cancer investigator. ..
  27. PATERNAL EXPOSURE AND SPORADIC BILATERAL RETINOBLASTOMA
    Greta Bunin; Fiscal Year: 2005
    ..Sporadic heritable RBL is a childhood cancer worth studying in its own right and an ideal model for the investigation of new germline mutation. ..
  28. COORDINATED REGULATION OF ANTIOXIDANT ENZYMES
    Michael Kelner; Fiscal Year: 2005
    ..abstract_text> ..